Go Pro
→ Elon will prove them wrong again (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AC Immune stock logo
ACIU
AC Immune
$2.72
-3.2%		$2.61
$2.10
▼
$4.00
$277.33M1.56165,371 shs320,246 shs
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$16.98
-2.1%		$16.26
$7.78
▼
$34.10
$249.23M1.46111,705 shs175,415 shs
InflaRx N.V. stock logo
IFRX
InflaRx
$1.72
+0.6%		$2.00
$0.80
▼
$2.95
$253.47M2.59458,298 shs422,111 shs
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
$1.47
+9.7%		$1.49
$1.26
▼
$3.20
$77.15M0.0583,267 shs82,518 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AC Immune stock logo
ACIU
AC Immune
0.00%+7.94%-7.17%+8.37%-10.53%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
0.00%-6.81%+8.64%-22.82%+67.95%
InflaRx N.V. stock logo
IFRX
InflaRx
0.00%-8.99%-22.87%-23.21%+26.47%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
0.00%+6.52%-5.16%-6.37%-26.87%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AC Immune stock logo
ACIU
AC Immune
$2.72
-3.2%		$2.61
$2.10
▼
$4.00
$277.33M1.56165,371 shs320,246 shs
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$16.98
-2.1%		$16.26
$7.78
▼
$34.10
$249.23M1.46111,705 shs175,415 shs
InflaRx N.V. stock logo
IFRX
InflaRx
$1.72
+0.6%		$2.00
$0.80
▼
$2.95
$253.47M2.59458,298 shs422,111 shs
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
$1.47
+9.7%		$1.49
$1.26
▼
$3.20
$77.15M0.0583,267 shs82,518 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AC Immune stock logo
ACIU
AC Immune
0.00%+7.94%-7.17%+8.37%-10.53%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
0.00%-6.81%+8.64%-22.82%+67.95%
InflaRx N.V. stock logo
IFRX
InflaRx
0.00%-8.99%-22.87%-23.21%+26.47%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
0.00%+6.52%-5.16%-6.37%-26.87%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AC Immune stock logo
ACIU
AC Immune
2.80
Moderate Buy$7.50175.74% Upside
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
2.00
Hold$69.00306.36% Upside
InflaRx N.V. stock logo
IFRX
InflaRx
2.67
Moderate Buy$7.43331.89% Upside
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
2.50
Moderate Buy$5.67285.49% Upside

Current Analyst Ratings Breakdown

Latest OKYO, GLSI, ACIU, and IFRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/2/2026
AC Immune stock logo
ACIU
AC Immune
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
9/29/2026
AC Immune stock logo
ACIU
AC Immune
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
9/24/2026
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
9/24/2026
AC Immune stock logo
ACIU
AC Immune
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/23/2026
AC Immune stock logo
ACIU
AC Immune
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$8.00
9/21/2026
InflaRx N.V. stock logo
IFRX
InflaRx
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/14/2026
InflaRx N.V. stock logo
IFRX
InflaRx
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$8.00
8/25/2026
InflaRx N.V. stock logo
IFRX
InflaRx
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/24/2026
AC Immune stock logo
ACIU
AC Immune
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/20/2026
AC Immune stock logo
ACIU
AC Immune
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$8.00
8/12/2026
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AC Immune stock logo
ACIU
AC Immune
$4.31M64.23N/AN/A$0.54 per share5.04
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/A$0.03 per shareN/A
InflaRx N.V. stock logo
IFRX
InflaRx
$30K8,449.21N/AN/A$0.65 per share2.65
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/A$0.30 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AC Immune stock logo
ACIU
AC Immune
-$85.03M-$0.54N/A16.00N/A-245.32%-100.17%-28.36%11/3/2026 (Estimated)
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$19.36M-$1.54N/AN/AN/AN/A-793.81%-295.32%11/13/2026 (Estimated)
InflaRx N.V. stock logo
IFRX
InflaRx
-$51.63M-$0.58N/AN/AN/AN/A-53.56%-43.02%11/9/2026 (Estimated)
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
-$8.95MN/AN/AN/AN/AN/AN/AN/A12/2/2026 (Estimated)

Latest OKYO, GLSI, ACIU, and IFRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.33-$0.27+$0.06-$0.27N/AN/A
8/7/2026Q2 2026
InflaRx N.V. stock logo
IFRX
InflaRx
-$0.0666-$0.11-$0.0434-$0.10$0.01 millionN/A
8/6/2026Q2 2026
AC Immune stock logo
ACIU
AC Immune
-$0.1044$0.03+$0.1344$0.0250$9.59 million$18.67 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AC Immune stock logo
ACIU
AC Immune
N/AN/AN/AN/AN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/AN/A
InflaRx N.V. stock logo
IFRX
InflaRx
N/AN/AN/AN/AN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AC Immune stock logo
ACIU
AC Immune
0.11
0.93
N/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/A
1.54
1.54
InflaRx N.V. stock logo
IFRX
InflaRx
N/A
8.22
8.22
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/A
2.43
2.43

Institutional Ownership

CompanyInstitutional Ownership
AC Immune stock logo
ACIU
AC Immune
51.36%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
4.16%
InflaRx N.V. stock logo
IFRX
InflaRx
42.39%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
2.97%

Insider Ownership

CompanyInsider Ownership
AC Immune stock logo
ACIU
AC Immune
4.60%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
51.47%
InflaRx N.V. stock logo
IFRX
InflaRx
16.30%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
40.46%
CompanyEmployeesShares OutstandingFree FloatOptionable
AC Immune stock logo
ACIU
AC Immune
106101.77 million97.09 millionOptionable
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
1314.68 million7.12 millionNot Optionable
InflaRx N.V. stock logo
IFRX
InflaRx
65147.37 million123.35 millionOptionable
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
552.48 million31.25 millionNot Optionable

Recent News About These Companies

OKYO Pharma (NASDAQ:OKYO) Stock Price Up 9.7% - Still a Buy?
October 3 at 1:41 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081476
OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences
September 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3370644/0/en/okyo-pharma-presents-and-participates-at-upcoming-ophthalmic-scientific-conferences.html
OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026
September 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/09/3358501/0/en/okyo-pharma-to-present-at-ophthalmology-futures-european-forum-and-inovation-day-at-escrs-2026.html
OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3357477/0/en/okyo-pharma-to-participate-in-a-fireside-chat-at-the-cantor-global-healthcare-conference.html
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
July 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/28/3334117/0/en/okyo-pharma-announces-purchase-of-shares-by-chief-scientific-officer.html
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
July 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/27/3333362/0/en/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026.html
OKYO Pharma outlines path to phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain
July 25, 2026  |  ophthalmologytimes.comO
OKYO Pharma Announces Purchase of Shares by Director
July 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/23/3332413/0/en/okyo-pharma-announces-purchase-of-shares-by-director.html
OKYO Pharma Announces Purchase of Shares by Chief Executive Officer
July 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/23/3331994/0/en/okyo-pharma-announces-purchase-of-shares-by-chief-executive-officer.html
OKYO Pharma Announces Purchase of Shares by Chairman
July 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/22/3331587/0/en/okyo-pharma-announces-purchase-of-shares-by-chairman.html
OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director
July 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/22/3331510/0/en/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director.html
OKYO Pharma Announces Purchase of Shares by Chief Medical Officer
July 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/22/3331223/0/en/okyo-pharma-announces-purchase-of-shares-by-chief-medical-officer.html
OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
July 21, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/okyo-pharma-to-present-at-the-h-c-wainwright-6th-annual-ophthalmology-virtual-conference-1036345995
OKYO Pharma Announces Purchase of Shares by Chairman
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330300/0/en/okyo-pharma-announces-purchase-of-shares-by-chairman.html
Small caps: Replenish Nutrients, OKYO Pharma, EDM Resources
July 20, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1095724?snapi
OKYO Pharma files annual report, highlights cash position and Phase 3 trial plans
July 20, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1095701?snapi
OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans
July 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/20/3329597/0/en/okyo-pharma-announces-filing-of-annual-report-with-strengthened-cash-position-and-accelerated-phase-3-plans.html
OKYO Pharma to Highlight Neuropathic Corneal Pain Program at Piper Sandler Virtual Ophthalmology Symposium
July 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/OKYO/pressreleases/3181476/okyo-pharma-to-highlight-neuropathic-corneal-pain-program-at-piper-sandler-virtual-ophthalmology-symposium/
OKYO Pharma announces positive feedback from US FDA Type D Meeting and accelerates urcosimod into global phase 3 trial for NCP
July 11, 2026  |  pharmabiz.comP
OKYO Pharma advances toward Phase 3 FDA trial - ICYMI
July 11, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1095285?snapi

New MarketBeat Followers Over Time

Media Sentiment Over Time

AC Immune stock logo

AC Immune NASDAQ:ACIU

$2.72 -0.09 (-3.20%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$2.72 +0.00 (+0.18%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Greenwich LifeSciences stock logo

Greenwich LifeSciences NASDAQ:GLSI

$16.98 -0.37 (-2.13%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$17.25 +0.27 (+1.60%)
As of 10/2/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

InflaRx stock logo

InflaRx NASDAQ:IFRX

$1.72 +0.01 (+0.58%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$1.76 +0.04 (+2.44%)
As of 10/2/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

OKYO Pharma stock logo

OKYO Pharma NASDAQ:OKYO

$1.47 +0.13 (+9.70%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$1.45 -0.02 (-1.36%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas